Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type7 {: e; T# R0 H M; m' A
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 5 H. u# ]2 G' P* g- U( r5 U! ]
+ Author Affiliations
" V4 V9 A- f. f' @9 m6 w X1 ^% {% }7 n: o% F4 c
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 z9 a$ j$ o2 I- m' l2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
7 K7 q& N2 K" J6 m3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
1 ]3 O6 D( s' M2 @4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
; c4 }) k) m- H* b3 q( y5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan , { d) P: Z: E* @* o- {% I; X2 o6 R* E
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
0 Z4 D) ]$ A3 {, j+ u: q7Kinki University School of Medicine, Osaka 589-8511, Japan 7 i6 t v0 ^" V/ A
8Izumi Municipal Hospital, Osaka 594-0071, Japan & L$ `7 L8 Y- f- C& W0 ^* P
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
4 C8 H/ j* ^; T8 s- } ]Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp , Q) ^4 l, Q; P$ V4 m. J
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
* S7 P8 p; W0 U' h0 S5 f+ |
! P3 k6 }5 J, g4 M$ H: q* i |